

**LISTING OF CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-59 (canceled)

Claim 60 (previously amended): A method for inhibiting  $\alpha_v\beta_5$  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an  $\alpha_v\beta_5$  antagonist, wherein said antagonist is a matrix metalloproteinase polypeptide that includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 15, 17, 19, 20, 21 or 22.

Claims 61-64 (canceled)

Claim 65 (previously added): The method of claim 60 wherein said tissue is human tissue.

Claim 66 (previously added): The method of claim 65 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

Claim 67 (previously added): The method of claim 60 wherein said tissue is arthritic.

Claim 68 (previously added): The method of claim 67 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim 69 (previously added): The method of claim 60 wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim 70 (previously added): The method of claim 69 wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim 71 (previously added): The method of claim 60 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim 72 (previously added): The method of claim 71 wherein said tissue is a carcinoma.

Claim 73 (previously added): The method of claim 71 wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim 74 (previously added): The method of claim 71 wherein said administering is conducted in conjunction with chemotherapy.

Claim 75 (previously added): The method of claim 60 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 76 (previously added): The method of claim 60 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 77 (previously added): The method of claim 60 wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 78 (previously added): The method of claim 60 wherein said administering comprises a single dose intravenously.

Claim 79 (previously added): The method of claim 60 wherein said administering comprises one or more dose administrations daily for one or more days.

Claim 80 (previously added): The method of claim 60 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

Claim 81 (previously added): The method of claim 60 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

Claim 82 (previously added): The method of claim 60 wherein said angiogenesis is induced by a cytokine.

Claim 83 (previously added): The method of claim 82 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- $\alpha$  and epidermal growth factor.

Claim 84 (previously added): The method of claim 82 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.

Claims 85-87 (canceled)

Claim 88 (new): A method for inhibiting  $\alpha_v\beta_3$  mediated angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an  $\alpha_v\beta_3$  antagonist, wherein said antagonist is an organic compound selected from the group consisting of compounds 7, 9, 10, 12, and 14.

Claim 89 (new): The method of claim 88 wherein said tissue is human tissue.

Claim 90 (new): The method of claim 89 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

Claim 91 (new): The method of claim 88 wherein said tissue is arthritic.

Claim 92 (new): The method of claim 91 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

Claim 93 (new): The method of claim 88 wherein said tissue is the retinal tissue and said angiogenesis is retinal angiogenesis.

Claim 94 (new): The method of claim 93 wherein said retinal tissue is in a patient with diabetic retinopathy or macular degeneration.

Claim 95 (new): The method of claim 88 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

Claim 96 (new): The method of claim 95 wherein said tissue is a carcinoma.

Claim 97 (new): The method of claim 95 wherein said solid tumor is a tumor of lung, pancreas, breast, colon, larynx or ovary.

Claim 98 (new): The method of claim 95 wherein said administering is conducted in conjunction with chemotherapy.

Claim 99 (new): The method of claim 88 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

Claim 100 (new): The method of claim 88 wherein said angiogenesis-inhibiting amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 101 (new): The method of claim 88 wherein said therapeutically effective amount is from about 0.1 mg/kg to about 300 mg/kg.

Claim 102 (new): The method of claim 88 wherein said administering comprises a single dose intravenously.

Claim 103 (new): The method of claim 88 wherein said administering comprises one or more dose administrations daily for one or more days.

Claim 104 (new): The method of claim 88 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

Claim 105 (new): The method of claim 88 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

Claim 106 (new): The method of claim 88 wherein said angiogenesis is induced by a cytokine.

Claim 107 (new): The method of claim 106 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- $\alpha$  and epidermal growth factor.

Claim 108 (new): The method of claim 106 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.